NEW YORK (GenomeWeb News) – Illumina and Partners HealthCare today announced a deal offering medical geneticists and pathologists infrastructure and networking tools for interpreting and reporting genetic sequencing data.
The tools will integrate Illumina's MiSeq desktop sequencing platform with Partners' GeneInsight Suite, an IT platform for analyzing and reporting complex genetic test results, which is registered with the US Food and Drug Administration as a Class I exempt medical device. According to Illumina and Partner, the solution "creates a seamless workflow, starting on the MiSeq and delivering results directly into the GeneInsight tool."
The partnership, the companies said in a statement, "enable[s] a comprehensive sequencing and clinically relevant reporting solution for the Illumina family of next-generation-based content sets." Illumina announced separately today the launch of five TruSight targeted sequencing content sets for autism, cancer, cardiomyopathy, and inherited disease, as well as an exome content set.
The new tools from the alliance with Partners will link to Illumina's BaseSpace cloud computing platform, the MyGenome app for the iPad, and a clinical lab's local laboratory information system.
The companies will release the combined MiSeq-GeneInsight solution to select pilot customers in the clinical testing space, including reference labs at leading academic institutions, molecular and genetic pathology labs which want to bring next-gen sequencing-based genetic testing in house, and commercial reference labs.
Illumina will also use the GeneInsight Lab application in its CLIA lab for clinical interpretation and reporting, they said.
Financial and other terms of the deal were not disclosed.